ModifiedBlue Cross Blue Shield - New MexicoPolicy CPCPLAB008

Diagnostic Testing of Iron Homeostasis and Metabolism

Defines reimbursement criteria and coding guidance for laboratory testing of iron homeostasis and metabolism (including serum ferritin and transferrin saturation) for BCBSNM members; plan documents and provider contracts govern if conflicts arise.

Policy Summary

PayerBlue Cross Blue Shield - New Mexico

PolicyDiagnostic Testing of Iron Homeostasis and Metabolism

Policy CodePolicy CPCPLAB008

Change TypeClarification and minor operational edits

Effective DateApril 15, 2025

Next Review DateN/A

Key ActionProviders must submit accurate documentation and may be asked to provide additional records; claims are subject to review against plan documents, contracts, medical policies, and coding logic.

SourceLink

POLICY UPDATE CHANGES

Removed "using serum iron and serum iron binding capacity measurements)" from #2 of Reimbursement Information.

Edited #3 to clarify that testing outside of conditions mentioned is not allowed and now states: For all other situations not addressed above, measurement of ferritin or transferrin levels, including transferrin saturation, is not reimbursable.

References were revised (some added, some removed) across multiple updates.

1.0policy version

2025-04-15policy effective date

2025-01-23approval date

hepcidin

Policy Summary

PayerBlue Cross Blue Shield - New Mexico

PolicyDiagnostic Testing of Iron Homeostasis and Metabolism

Policy CodePolicy CPCPLAB008

Change TypeClarification and minor operational edits

Effective DateApril 15, 2025

Next Review DateN/A

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Reimbursement and Coverage Criteria

Reimbursement criteria for iron studies

Measurement of serum ferritin and transferrin saturation may be reimbursable in the specified clinical situations below; certain tests are explicitly excluded.

ALL of the following

Serum ferritin measurement reimbursable for any of the following:
- For the evaluation and monitoring of iron overload disorders.
- For the evaluation of an individual with abnormal hemoglobin and/or hematocrit levels.
- For individuals with symptoms of hemochromatosis (see Note 1).
  See Note 1 for symptoms: fatigue; joint pain; unexplained weight loss; abdominal pain; abnormal bronze or gray skin color; loss of sex drive.
- For individuals with first-degree relatives with confirmed hereditary hemochromatosis (HH).
  First-degree relatives include parents, full siblings, and children.
- For the evaluation of individuals with liver disease.
- For the evaluation of hemophagocytic lymphohistiocytosis (HLH) and Still disease.
- In males with secondary hypogonadism.
- For the evaluation and monitoring of patients with chronic kidney disease who are receiving or being considered for receiving treatment for anemia; testing frequency: every 1 to 3 months.
Serum transferrin saturation reimbursable for any of the following:
- For the evaluation of iron overload in individuals with symptoms of hemochromatosis (see Note 1).
- For the evaluation of iron overload in individuals with first-degree relatives with confirmed hereditary hemochromatosis (HH).
- For the evaluation of iron deficiency anemia.
ALL of the following
- For all other situations not addressed above, measurement of ferritin or transferrin levels, including transferrin saturation, is not reimbursable.
- Serum hepcidin testing, including immunoassays, is not reimbursable.
- The use of GlycA testing to measure or monitor transferrin or other glycosylated proteins is not reimbursable.

ALL of the following

Note 1: Symptoms of hemochromatosis per NIDDK include fatigue; joint pain; unexplained weight loss; abdominal pain; abnormal bronze or gray skin color; loss of sex drive.
Note 2: First-degree relatives include parents, full siblings, and children of the individual.

Reimbursement criteria summary

Recent policy language clarifies reimbursable versus non-reimbursable testing.

ALL of the following

Removed phrasing referencing serum iron and serum iron binding capacity measurements from the reimbursement item #2 description (operational change).
Clarified exclusion: For all other situations not addressed above, measurement of ferritin or transferrin levels, including transferrin saturation, is not reimbursable.
Reiterated explicit non-reimbursable tests: serum hepcidin testing (including immunoassays) and use of GlycA testing to measure or monitor transferrin or other glycosylated proteins are not reimbursable.

Procedure Codes, Coding Guidance, and Monitoring

Procedure codes guidancemixed

Document states code lists are not all-encompassing; inclusion of a code does not guarantee coverage.

Reimbursement coding notesmixed

No codes listed

Monitoring frequency for CKD patients on/considered for anemia treatment

Recommended monitoring intervalEvery 1 to 3 months for patients with chronic kidney disease who are receiving or being considered for treatment for anemia (including individuals on iron therapy).

Applicable populationPatients with chronic kidney disease (CKD) who are receiving or being considered for iron or anemia treatment.

Trigger for testingInitiation of iron therapy, ongoing iron therapy, or clinical decision to consider iron or anemia treatment in CKD patients.

Purpose of monitoringEvaluation and monitoring of iron status to guide therapy and assess response or safety (e.g., iron overload or deficiency concerns).

Provider Responsibilities and Authorization

Documentation Required

Submit accurate documentation and support claims upon request

Providers are responsible for submitting accurate documentation of services performed and must code claims using valid HIPAA-approved code sets and industry-standard coding guidelines. Claims are subject to review and, upon request, providers are urged to submit any additional documentation to support the claim.

Use valid code combinations from HIPAA-approved code sets (CPT, HCPCS, ICD-10-CM/PCS, etc.).
Code claims according to industry standard guidelines (UB editor, AMA CPT Assistant, NCCI, DRG rules, CMS policies).
Be prepared to provide additional documentation upon request; claims are subject to review against plan terms, provider contracts, medical policies, CPCPs, and coding software logic.

Denial Risk

Ferritin/transferrin testing not reimbursable outside specified indications

Measurement of ferritin or transferrin levels, including transferrin saturation, is not reimbursable for any situations not specifically listed as reimbursable in the policy.

Definitions and Test Descriptions

Plan documents — definition and governance

What plan documents includeCertificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents.

Governance roleIf a conflict arises between a Clinical Payment and Coding Policy (CPCP) and a plan document under which a member is entitled to Covered Services, the plan document will govern.

Provider contract precedenceIf a conflict arises between a CPCP and any provider contract pursuant to which a provider participates in providing Covered Services, the provider contract will govern.

Interpretation discretionBlue Cross and Blue Shield of New Mexico may use reasonable discretion in interpreting and applying this policy and has final discretionary authority to the extent provided under applicable plan documents.

Iron-status laboratory tests — definitions and interpretation